To date, however, the only biologic ever to be produced in Taiwan for the market is Adimmune's vaccine, which generated sales of NT $ 190 million last year.
但除了國光疫苗早已成立逾 40 年、去年營收約台幣 1.9 億元之外，我國至今還沒有其他任何生物製劑產品上市。